MOTS-c: Mitochondrial Peptide and Exercise Mimetic Research Guide

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of the mitochondrial genome. Identified by Lee et al. in 2015 (Cell Metabolism), MOTS-c represents a class of mitochondria-derived peptides (MDPs) that function as retrograde signals — communication from mitochondria back to the nucleus and other cellular compartments to regulate metabolic state.

Its mitochondrial origin distinguishes it from nuclear-encoded peptide hormones. MOTS-c circulates systemically and is found in human plasma, where its levels correlate with metabolic health markers in clinical cohort studies.

MOTS-c's primary identified mechanism involves activation of AMPK (AMP-activated protein kinase) — a master regulator of cellular energy homeostasis. AMPK activation triggers a metabolic programme that increases fatty acid oxidation, improves glucose uptake, and enhances mitochondrial biogenesis.

Specific mechanisms identified in published research include:

• AMPK phosphorylation — MOTS-c activates AMPK in skeletal muscle, liver, and adipose tissue, mimicking the metabolic response to exercise
• Folate cycle inhibition — MOTS-c inhibits the de novo purine synthesis pathway in the folate cycle, resulting in AICAR accumulation, which in turn activates AMPK
• Nuclear translocation — under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it modulates gene expression via interaction with nuclear transcription factor targets
• Insulin sensitisation — skeletal muscle studies show MOTS-c enhances insulin-stimulated glucose uptake independently of insulin receptor signalling

MOTS-c is described as an exercise mimetic because its administration in animal models reproduces several metabolic adaptations associated with physical exercise — including improved insulin sensitivity, increased fat oxidation, and AMPK activation in skeletal muscle — without the mechanical stimulus of exercise itself.

A 2021 study in Nature Communications demonstrated that MOTS-c levels increase in human plasma during exercise and that administration of exogenous MOTS-c to aged mice improved exercise performance and metabolic flexibility. This has positioned MOTS-c as a research tool for studying exercise adaptation pathways and age-related metabolic decline.

Plasma MOTS-c levels decline with age in human studies, and supercentenarians (individuals over 105 years) have been found to have specific MOTS-c genetic variants associated with increased mitochondrial efficiency. These observations have generated research interest in MOTS-c as a biomarker and potential mediator of metabolic longevity.

Animal studies using aged mouse models have shown MOTS-c administration can partially restore youthful metabolic parameters including insulin sensitivity, physical capacity, and mitochondrial respiratory function — making it a subject of active investigation in the longevity research field.

RetaLABS MOTS-c is supplied as lyophilised powder in 10mg and 40mg vial sizes. Reconstitute with bacteriostatic water, store lyophilised at −20°C, and use reconstituted solution within 4 weeks at 2–8°C.

See the Peptide Reconstitution Guide for detailed protocol notes. Each batch is supplied with a COA — available on request at the RetaLABS team. All products are for laboratory research use only.